CD133: a stem cell biomarker and beyond
TLDR
New insights into CD133 regulation and the involvement of CD133 in cell self-renewal, tumorigenesis, metastasis, resistance, metabolism, differentiation, autophagy, apoptosis, and regeneration are summarized.Abstract:
Cancer stem cells (CSCs) or tumor initiating cells (TICs) contribute to tumorigenesis, metastasis, recurrence and chemoresistance. CD133, a pentaspan membrane glycoprotein, has been used as a stem cell biomarker for isolation of stem-like cells from a variety of normal and pathological tissues as well as cell lines since its discovery in 1999. Recent studies are focusing on the functionality of CD133. In this review, we summarize new insights into CD133 regulation and the involvement of CD133 in cell self-renewal, tumorigenesis, metastasis, resistance, metabolism, differentiation, autophagy, apoptosis, and regeneration.read more
Citations
More filters
Journal ArticleDOI
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Alex M. Abel,Alex M. Abel,Chao Yang,Chao Yang,Monica S. Thakar,Monica S. Thakar,Subramaniam Malarkannan +6 more
TL;DR: Recent advances made in the understanding of how NK cells develop, mature, and their potential translational use in the clinic are summarized.
Journal ArticleDOI
Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.
Lia Walcher,Ann-Kathrin Kistenmacher,Huizhen Suo,Reni Kitte,Sarah Dluczek,Alexander Strauß,André-René Blaudszun,Tetyana Yevsa,Stephan Fricke,Uta Kossatz-Boehlert +9 more
TL;DR: It is pointed out, that it is crucial to identify and monitor residual CSCs, senescent tumor cells, and the pro-tumorigenic senescence-associated secretory phenotype in a therapy follow-up using specific biomarkers.
Journal ArticleDOI
Cancer stem cells in colorectal cancer: a review.
TL;DR: This review summarises current literature on the understanding of CSCs in CRC, including evidence of the presence of C SC subpopulations, and the stem cell markers currently used to identify and localise these CSCSubpopulations.
Journal ArticleDOI
The roles of mesenchymal stem cells in tumor inflammatory microenvironment.
TL;DR: Studies of the mechanisms by which interactions among tumors, MSCs, and the inflammatory microenvironment occur and methods to disrupt these interactions will likely reveal new targets for cancer therapy.
Journal ArticleDOI
Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application.
TL;DR: An overview of the Notch signal in NSCLC is provided: its biological significance and therapeutic application, which shows promising effect in some cancer patients received treatment with Notch1 inhibitor.
References
More filters
Journal ArticleDOI
AC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells
Amy Yin,Sheri Miraglia,Esmail D. Zanjani,Graça Almeida-Porada,Makio Ogawa,Anne G. Leary,Johanna Olweus,John F. Kearney,David William Buck +8 more
TL;DR: AC133-selected cells engraft successfully in a fetal sheep transplantation model, and human cells harvested from chimeric fetal sheep bone marrow have been shown to successfully engraft secondary recipients, providing evidence for the long-term repopulating potential of AC133(+) cells.
Journal ArticleDOI
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Dagmar Beier,Peter Hau,Martin Proescholdt,Annette Lohmeier,Jörg Wischhusen,Peter J. Oefner,Ludwig Aigner,Alexander Brawanski,Ulrich Bogdahn,Christoph P. Beier +9 more
TL;DR: Together, the data provide first evidence that CD133(+) CSC maintain only a subset of primary glioblastomas, with apparent stem cell-like properties but distinct molecular profiles and growth characteristics in vitro and in vivo.
Journal ArticleDOI
A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning.
Sheri Miraglia,Wayne R. Godfrey,Amy Yin,Kristin Atkins,Roger A. Warnke,Jeannine T. Holden,Robert A. Bray,Edmund K. Waller,David William Buck +8 more
TL;DR: The molecular cloning of a cDNA encoding this antigen is reported and it is shown that it does not share homology with any previously described hematopoietic or other cell surface antigen(s).
Journal ArticleDOI
CD133 expression is not restricted to stem cells, and both CD133 + and CD133 – metastatic colon cancer cells initiate tumors
Sergey V. Shmelkov,Jason M. Butler,Andrea T. Hooper,Adilia Hormigo,Jared S Kushner,Till Milde,Ryan St Clair,Muhamed Baljevic,Ian A. White,David K. Jin,Amy Chadburn,Andrew J. Murphy,David M. Valenzuela,Nicholas W. Gale,Gavin Thurston,George D. Yancopoulos,Michael I. D’Angelica,Nancy E. Kemeny,David Lyden,Shahin Rafii +19 more
TL;DR: The data suggest that CD133 expression is not restricted to intestinal stem or cancer-initiating cells, and during the metastatic transition, CD133+ tumor cells might give rise to the more aggressive CD133(- )subset, which is also capable of tumor initiation in NOD/SCID mice.
Journal ArticleDOI
CD133 + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway
TL;DR: Results show that CD133+ HCC cells contribute to chemoresistance through preferential activation of Akt/PKB and Bcl-2 cell survival response, and targeting of this specific survival signaling pathway in CD133- HCC CSCs may provide a novel therapeutic model for the disease.